INBX (Inhibrx Biosciences) Land And Improvements : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Inhibrx Biosciences Land And Improvements?

Inhibrx Biosciences's land and improvements for the quarter that ended in Dec. 2024 was $0.00 Mil.

Inhibrx Biosciences Land And Improvements Historical Data

The historical data trend for Inhibrx Biosciences's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inhibrx Biosciences Land And Improvements Chart

Inhibrx Biosciences Annual Data

Trend

Dec22

Dec23

Dec24

Land And Improvements

Inhibrx Biosciences Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Land And Improvements	Get a 7-Day Free Trial				-	-	-	-	-

Inhibrx Biosciences Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Inhibrx Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inhibrx Biosciences Inc (NAS:INBX) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037

Website

https://www.inhibrx.com

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.